Shinichiro Katayanagi is Executive Vice President, Corporate Development and Licensing at Sunovion Pharmaceuticals Inc., a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Mr. Katayanagi joined Sunovion in 2017 and is a member of the Executive Leadership Team.
Mr. Katayanagi is responsible for helping guide business strategy for the Company and advancing Sunovion’s track record of discovery, development and commercialization of important psychiatric, neurological and respiratory therapies.
He also serves as Senior Strategic Officer for North America non-oncology business for Sumitomo Dainippon Pharma Co. Ltd., the parent company of Sunovion.
Mr. Katayanagi has more than 24 years of experience in US and global pharmaceutical operations, corporate strategy, management and finance.
Previously, Mr. Katayanagi held leadership positions at Astellas Pharma Inc. and Yamanouchi Pharmaceutical Company. He had a lead role in proposing the 2005 merger that created Astellas through the integration of Yamanouchi and Fujisawa Pharmaceutical Company, and was responsible for establishing the Astellas corporate vision and long-term and mid-term business strategies.
Mr. Katayanagi was Executive Vice president and Chief Financial Officer, Astellas US Inc., prior to assuming responsibilities as Corporate Officer and President of Asia International for Astellas Pharma Inc. and serving as a member of the Executive Management Committee.
He earned his Bachelor of Laws degree in Political Science at Keio University in Tokyo.